FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2344741169> ?p ?o ?g. }

• W2344741169 abstract "Etomidate is a potent hypnotic agent with several desirable advantages such as providing a stable cardiovascular profile with minimal respiratory adverse effects and better hemodynamic stability compared with other induction agents. This drug is associated, however, with myoclonic movements which is characterized by a sudden, brief muscle contractions as a disturbing side-effect.The present study was designed to compare the effectiveness of low- dose midazolam, magnesium sulfate, remifentanil and low-dose etomidate to suppress etomidate-induced myoclonus in orthopedic surgery.A double-blind clinical trial study was conducted in an academic hospital from September 2014 to August 2015. Two hundred and eighty-four eligible patients, American society of anesthesiologists class I - II, scheduled for elective orthopedic surgery were randomly allocated into four equal groups (n = 71). They received premedication with intravenous low-dose midazolam 0.015 mg/kg, magnesium sulfate 30 mg/kg, remifentanil 1 μg/kg and low-dose etomidate 0.03 mg/kg two minutes before induction of anesthesia with 0.3 mg/kg intravenous etomidate. Then the incidence and intensity of myoclonus were evaluated on a scale of 0 - 3; 0 = no myoclonus; 1 = mild (movement at wrist); 2 = moderate (movement at arm only, elbow or shoulder); and 3 = severe, generalized response or movement in more than one extremity, within ninety seconds. Any adverse effect due to these premedication agents was recorded.The incidence and intensity of myoclonus were significantly lower in the low-dose etomidate group. The incidence rates of myoclonus were 51 (71.85%), 61 (85.9%), 30 (42.3%) and 41 (57.7%), and the percentages of patients who experienced grade III of myoclonus were 30 (58.8%), 32 (52.5%), 9 (30%) and 14 (34.1%) in the midazolam, magnesium sulfate, etomidate and remifentanil groups, respectively. The incidence and intensity of myoclonus were significantly lower in the low-dose etomidate group (P = 0.0001). No notable adverse effect was detected in our patients during the study period.Intravenous etomidate 0.03 mg/kg prior to induction can effectively reduce the incidence and severity of myoclonus linked to etomidate." @default.
• W2344741169 created "2016-06-24" @default.
• W2344741169 creator A5000012007 @default.
• W2344741169 creator A5002563818 @default.
• W2344741169 creator A5006636981 @default.
• W2344741169 creator A5007796637 @default.
• W2344741169 creator A5009605957 @default.
• W2344741169 creator A5076037770 @default.
• W2344741169 creator A5079565110 @default.
• W2344741169 date "2016-04-02" @default.
• W2344741169 modified "2023-10-16" @default.
• W2344741169 title "Comparison of the Effects of Low-Dose Midazolam, Magnesium Sulfate, Remifentanil and Low-Dose Etomidate on Prevention of Etomidate-Induced Myoclonus in Orthopedic Surgeries" @default.
• W2344741169 cites W1181165592 @default.
• W2344741169 cites W1591425581 @default.
• W2344741169 cites W1624037464 @default.
• W2344741169 cites W170291426 @default.
• W2344741169 cites W1791985834 @default.
• W2344741169 cites W1965969375 @default.
• W2344741169 cites W2000576585 @default.
• W2344741169 cites W2012647258 @default.
• W2344741169 cites W2019850318 @default.
• W2344741169 cites W2029816524 @default.
• W2344741169 cites W2036327842 @default.
• W2344741169 cites W2037179138 @default.
• W2344741169 cites W2037184064 @default.
• W2344741169 cites W2040705260 @default.
• W2344741169 cites W2042862543 @default.
• W2344741169 cites W2045821109 @default.
• W2344741169 cites W2054859181 @default.
• W2344741169 cites W2062465459 @default.
• W2344741169 cites W2112018162 @default.
• W2344741169 cites W2123921747 @default.
• W2344741169 cites W2125286392 @default.
• W2344741169 cites W2125671254 @default.
• W2344741169 cites W2126216563 @default.
• W2344741169 cites W2126717013 @default.
• W2344741169 cites W2131512913 @default.
• W2344741169 cites W2143793323 @default.
• W2344741169 cites W2152160455 @default.
• W2344741169 cites W2158471250 @default.
• W2344741169 cites W2159751709 @default.
• W2344741169 cites W2161329388 @default.
• W2344741169 cites W2165382446 @default.
• W2344741169 cites W2368676007 @default.
• W2344741169 cites W4232905896 @default.
• W2344741169 cites W1491796556 @default.
• W2344741169 doi "https://doi.org/10.5812/aapm.35333" @default.
• W2344741169 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4885461" @default.
• W2344741169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27247915" @default.
• W2344741169 hasPublicationYear "2016" @default.
• W2344741169 type Work @default.
• W2344741169 sameAs 2344741169 @default.
• W2344741169 citedByCount "26" @default.
• W2344741169 countsByYear W23447411692016 @default.
• W2344741169 countsByYear W23447411692017 @default.
• W2344741169 countsByYear W23447411692018 @default.
• W2344741169 countsByYear W23447411692019 @default.
• W2344741169 countsByYear W23447411692020 @default.
• W2344741169 countsByYear W23447411692021 @default.
• W2344741169 countsByYear W23447411692022 @default.
• W2344741169 countsByYear W23447411692023 @default.
• W2344741169 crossrefType "journal-article" @default.
• W2344741169 hasAuthorship W2344741169A5000012007 @default.
• W2344741169 hasAuthorship W2344741169A5002563818 @default.
• W2344741169 hasAuthorship W2344741169A5006636981 @default.
• W2344741169 hasAuthorship W2344741169A5007796637 @default.
• W2344741169 hasAuthorship W2344741169A5009605957 @default.
• W2344741169 hasAuthorship W2344741169A5076037770 @default.
• W2344741169 hasAuthorship W2344741169A5079565110 @default.
• W2344741169 hasBestOaLocation W23447411692 @default.
• W2344741169 hasConcept C141071460 @default.
• W2344741169 hasConcept C2776277131 @default.
• W2344741169 hasConcept C2776538686 @default.
• W2344741169 hasConcept C2776814716 @default.
• W2344741169 hasConcept C2777602617 @default.
• W2344741169 hasConcept C2778000748 @default.
• W2344741169 hasConcept C2778300832 @default.
• W2344741169 hasConcept C2778891214 @default.
• W2344741169 hasConcept C2779676917 @default.
• W2344741169 hasConcept C42219234 @default.
• W2344741169 hasConcept C71924100 @default.
• W2344741169 hasConceptScore W2344741169C141071460 @default.
• W2344741169 hasConceptScore W2344741169C2776277131 @default.
• W2344741169 hasConceptScore W2344741169C2776538686 @default.
• W2344741169 hasConceptScore W2344741169C2776814716 @default.
• W2344741169 hasConceptScore W2344741169C2777602617 @default.
• W2344741169 hasConceptScore W2344741169C2778000748 @default.
• W2344741169 hasConceptScore W2344741169C2778300832 @default.
• W2344741169 hasConceptScore W2344741169C2778891214 @default.
• W2344741169 hasConceptScore W2344741169C2779676917 @default.
• W2344741169 hasConceptScore W2344741169C42219234 @default.
• W2344741169 hasConceptScore W2344741169C71924100 @default.
• W2344741169 hasIssue "2" @default.
• W2344741169 hasLocation W23447411691 @default.
• W2344741169 hasLocation W23447411692 @default.
• W2344741169 hasLocation W23447411693 @default.
• W2344741169 hasLocation W23447411694 @default.
• W2344741169 hasOpenAccess W2344741169 @default.
• W2344741169 hasPrimaryLocation W23447411691 @default.
• W2344741169 hasRelatedWork W1990074637 @default.

• next